about
Update in juvenile myositisAdvances in the treatment of polyarticular juvenile idiopathic arthritisThe lived experience of juvenile idiopathic arthritis in young people receiving etanercept.Structural and functional insights of RANKL-RANK interaction and signalingDense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis.Immunological characteristics and T-cell receptor clonal diversity in children with systemic juvenile idiopathic arthritis undergoing T-cell-depleted autologous stem cell transplantation.Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection.Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression.Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in αβ and γδ T cells.Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral bloodTh17 plasticity in human autoimmune arthritis is driven by the inflammatory environmentHypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis.Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity.Association of the IL-10 gene family locus on chromosome 1 with juvenile idiopathic arthritis (JIA).Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.Labeling antigen-specific CD4(+) T cells with class II MHC oligomers.Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cellsJuvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.A novel dried blood spot-LCMS method for the quantification of methotrexate polyglutamates as a potential marker for methotrexate use in children.Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis.Agreement between proxy and adolescent assessment of disability, pain, and well-being in juvenile idiopathic arthritisAutologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityGenotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patientsJuvenile dermatomyositis: new insights and new treatment strategies.Paediatric idiopathic inflammatory muscle disease: recognition and management.Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritisSynovial Regulatory T Cells Occupy a Discrete TCR Niche in Human Arthritis and Require Local Signals To Stabilize FOXP3 Protein ExpressionThe experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people.Juvenile-onset inflammatory arthritis: a study of adolescents' beliefs about underlying cause.HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.
P50
Q26822598-FAFDED96-2806-4724-99E3-F3F39A140E54Q27001017-E82E821D-A3EE-4009-B544-15C4FCDD4B0BQ27303519-264DAEF9-531A-4A89-BB11-406F076A2903Q27661741-6327602D-C18C-492D-80A3-E92244A985D7Q30416148-7A815D77-4273-4C76-BA41-F30EF835B4BBQ33559048-C76B03B2-9514-4126-B2B6-00F70CC77BA2Q33750260-BD750408-22AF-4863-B833-67E81FE3C98DQ33815056-5BEE1170-C5BD-406D-A21F-6910B1227FF1Q33921394-EB61C055-9F85-469B-B41C-BC65CC812DE6Q34089662-0D28FB1D-52DE-4C1A-8B9A-7523FF1831F5Q34093086-0D3A7B2B-FF34-4670-A86F-CCA1190ADCDBQ34146288-9784A7CE-9504-4C5D-8C91-8F21F6E7F1A8Q34235121-46E612C9-6729-410A-A26D-244EDD7AE5CFQ34310449-5C6CD210-6684-40EC-A99B-E71071D79344Q34456454-D05AAFC7-9BE5-4C9F-8FF6-A385389476D7Q34486301-6ABE9474-3826-4B94-8A0A-B6CDA1EC920EQ34490287-1BD1099D-6288-4532-8A4C-789DE1B55851Q34563223-EE825794-971E-4891-873E-1FB25067593DQ34815610-14505B79-6F86-4ACB-9B73-776A026EA1ACQ34896763-9B364FE7-6EA5-4469-80B6-15A4F0C544A2Q35009335-FD4C381C-05EB-4FB2-8F5A-7829C29866F4Q35082782-D523DB8F-8508-4698-B289-809F89CDF0D3Q35108331-F1A66B3E-FBFF-4AC6-8DD7-BF6AA544884DQ35204115-BFFB25F1-837B-48AE-A698-9147CC22B19FQ35456471-77DDEC29-30FA-4CE6-BDA7-AFF20B15B191Q35553325-00CA295B-5B5A-46A3-9C7C-326BF5AD714FQ35752908-FB028E14-FAA4-450C-B55C-2FAD2C49A607Q35755515-13705145-4378-44CC-8F4C-51EC2AD846E0Q35890979-339C8D20-8286-4BD9-9D81-AB3684B5D179Q35926593-3802F5DE-EC15-4735-8927-94719E8642BFQ35953233-4EAB9384-60A2-4681-B23D-5C7F263A4D0AQ36056490-00B807CD-328B-428F-9F69-04FAE1B3C3AAQ36059542-0B0A146F-F7F1-4F54-91D3-551CFFBA3398Q36174530-70E429BE-DC60-4413-AFEB-483710E1E18BQ36202845-B2E4B762-FE0D-4D5D-ADD6-FD67BEC1E3AFQ36252768-0718CA0F-B524-4F62-8BE8-E9FCC10E3BE9Q36350402-39763DA1-5893-489F-A13A-7870E3D32DC2Q36366049-DFF826DD-A840-43B3-A2C7-74798DF08141Q36434886-7A4603F3-45F8-4264-9809-39C4E78E93F9Q36435134-6A287095-A12A-44BA-9B37-B75A565DDB48
P50
description
researcher ORCID ID = 0000-0002-7495-1429
@en
wetenschapper
@nl
name
Lucy R Wedderburn
@ast
Lucy R Wedderburn
@en
Lucy R Wedderburn
@nl
type
label
Lucy R Wedderburn
@ast
Lucy R Wedderburn
@en
Lucy R Wedderburn
@nl
prefLabel
Lucy R Wedderburn
@ast
Lucy R Wedderburn
@en
Lucy R Wedderburn
@nl
P108
P108
P31
P496
0000-0002-7495-1429